Claim 6, line 1, change "Pharmaceutical" to --A pharmaceutical--;

lines 2 and 3, change "characterized in that it essentially consists of" to --consisting essentially of--;

line 5, change "either Claim 3 or Claim 4" to Claim 15;

Claim 7, lines 1 and 2, change "Formulation according to Claim 6, characterized in that" to --The formulation according to Claim 6, wherein--;

Claim 8, lines 1 and 2, change "Formulation according to Claim 7, characterized in that" to --The formulation according to Claim 6, wherein--

Claim 9, lines 1 and 2, change "Formulation according to any one of Claims 6 to 8, characterized in that" to --The formulation according to Claim 6, wherein--;

Claim 10, lines 1 and 2, change "Formulation according to any one of Claims 6 to 9, characterized in that it comprises to --The formulation according to Claim 6 comprising--;

line 7, after "derivative" insert --.-- and delete the remainder of the sentence;

Claim 11, line 1, change "Pharmaceutical" to --A pharmaceutical--;

lines 2 and 3, change "characterized in that it essentially consists of" to --consisting essentially of--;

line 4, change "either Claim 3 or Claim 4" to --Claim 15--;

Claim 12, line 1, change "Formulation" to --The formulation--;

line 2, change "characterized in that" to --wherein--.

Please add new claims as follows:

--13. A method of inhibiting HIV-1 infection comprising administering a recombinant HIV-1 envelope protein in which the V3 loop is partially or completely deleted, in an amount effective for inducing a humoral, cellular and mucosal immune response.

14. The method of claim 13 wherein the envelope protein is selected from the group consisting of the recombinant gp160 and gp120 Env proteins in which the V3 loop is partially deleted, and the recombinant gp160 and gp120 Env proteins in which the V3 loop is completely deleted.

15. A vaccine comprising a recombinant envelope protein according to claim 13 and at least one pharmaceutically acceptable vehicle.

16. The vaccine of claim 15 further comprising at least one compound selected from the group consisting of :

(1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminum hydroxide or calcium phosphate, and muramylpeptide derivatives and

(2) liposomes.

17. The vaccine of claim 15 wherein the envelope protein is anchored onto unilamellar synthetic lipid vesicles.

18. The vaccine of claim 17 wherein the vesicles comprise a molar ratio of phosphatidylcholine to cholesterol of about 8:1, and which have a size of between 70 and 150 nm.